- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT03865693
Effects of Pain Scrambler Therapy for the Alterations of Cerebral Blood
18. juni 2019 oppdatert av: Hangang Sacred Heart Hospital
Effects of Pain Scrambler Therapy for the Alterations of Cerebral Blood Volume in Pain Network of Neuropathic Pain on Burn Patients
Prevalence of chronic pain has been shown to be high after thermal injury.
Post-burn neuropathic pain causes chronic disabilities that is often difficult to treat effectively.
Pain Scrambler therapy is a patient-specific electrocutaneous nerve stimulation device.
To study changes in the pain network associated with neuropathic pain, magnetic resonance imaging(MRI) was used to evaluate cerebral blood volume(CBV) in patients who had been injuried by burn.
Participants (N=40, experimental 20 and control group 20) comprised patients with neuropathic pain after thermal injury.
The subjects complained of severe neuropathic pain that was rated at least 5 on the visual analogue scale (VAS), despite treatments with gabapentin medication and other physical modalities.
Each Scrambler therapy with the MC5-A Calmare® therapy device (Competitive Technologies, Inc. Fairfield, USA ) was performed for 40 min daily (Monday through Friday) for 10 consecutive days.
The stimulus was increased to the maximum intensity bearable by the individual patient without causing any additional pain or discomfort.
The intensity of neuropathic pain was measured using the visual analogue scale(VAS).
Depressive mood was assessed using the Beck Depression Scale.
Voxel-wise comparisons of relative CBV maps were made between before scrambler therapy and after 10 scrambler therapy sessions over the entire brain volume.
The relationship between individual participant CBV(measured in voxels), BDS and VAS score was also examined.
We observed decreased in the cerebral pain network of patients with burn injury.
Scrambler therapy is a non-invasive, non-medicinal modality that significantly reduced burn-associated neuropathic pain.
Scrambler therapy should be considered as a treatment option for burn survivors with severe neuropathic pain.
Studieoversikt
Detaljert beskrivelse
The groups (scrambler therapy and sham therapy) were randomly assigned.
All subjects were recruited in scrambler thrapy and sham stimulation.
Main study outcomes included group differences in CBV changed and the the relationship between CBV changes and neuropathic pain intensity.
These analyses were performed using the same framework of the general linear model, which was repeatedly applied to each voxel with the same coordinates.
Studietype
Intervensjonell
Registrering (Forventet)
40
Fase
- Ikke aktuelt
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiesteder
-
-
Yeong-deungpo-Dong
-
Seoul, Yeong-deungpo-Dong, Korea, Republikken, 150-719
- Rekruttering
- Hangang Sacred Heart Hospital
-
Hovedetterforsker:
- So Young Joo, M.D.
-
-
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
18 år til 65 år (Voksen, Eldre voksen)
Tar imot friske frivillige
Nei
Kjønn som er kvalifisert for studier
Alle
Beskrivelse
Inclusion Criteria:
- Burn patients
- severe neuropatic pain rated at least 5 on the 10-point numerical rating scale (NRS)
Exclusion Criteria:
- cardiac arrest history
- history of neurologi disease or brain surgery
- unstable heart disease or presence of a cardiac pacemaker
- pain resulting from other causes like as neuromuscular diseases
- psychiatric disorder
- diabetes mellitus
- abnormal renal function
- contraindication for MRI, or pregnancy.
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Enkelt
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: scarmbler treatment group
Each Scrambler therapy with the MC5-A Calmare® therapy device (Competitive Technologies, Inc. Fairfield, USA ) was performed for 40 min daily (Monday through Friday) for 10 consecutive days.
The experimental participants were received scarmbler therapy 10 times for 2 weeks.
The stimulus was increased to the maximum intensity bearable by the individual patient without causing any additional pain or discomfort.
|
Scrambler therapy is a patient-specific electrocutaneous nerve stimulation device.
|
|
Sham-komparator: sham treatment group
conservative management without scarmbler therapy
|
Scrambler therapy is a patient-specific electrocutaneous nerve stimulation device.
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
neuropathic pain score
Tidsramme: after 4 weeks scrambler therapy
|
visual analog scale, Zero ("0") represented no pain and 10 represented unbearable symptoms
|
after 4 weeks scrambler therapy
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Cerebral blood volume
Tidsramme: after 4 weeks scrambler therapy
|
Cerebral blood volume(CBV) is a hemodynamic variable that is highly correlated with oxygen metabolism, representing the fraction of cerebral tissue volume occupied by blood at a given time point.
|
after 4 weeks scrambler therapy
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Sponsor
Samarbeidspartnere
Etterforskere
- Hovedetterforsker: Cheong Hoon Seo, M.D., Hangang Sacred Heart Hospital
Publikasjoner og nyttige lenker
Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.
Generelle publikasjoner
- Joo SY, Cho YS, Cho SR, Kym D, Seo CH. Effects of pain Scrambler therapy for management of burn scar pruritus: A pilot study. Burns. 2017 May;43(3):514-519. doi: 10.1016/j.burns.2016.09.028. Epub 2016 Oct 15.
- Majithia N, Smith TJ, Coyne PJ, Abdi S, Pachman DR, Lachance D, Shelerud R, Cheville A, Basford JR, Farley D, O'Neill C, Ruddy KJ, Sparadeo F, Beutler A, Loprinzi CL. Scrambler Therapy for the management of chronic pain. Support Care Cancer. 2016 Jun;24(6):2807-14. doi: 10.1007/s00520-016-3177-3. Epub 2016 Apr 4.
- Lee SY, Park CH, Cho YS, Kim L, Yoo JW, Joo SY, Seo CH. Scrambler Therapy for Chronic Pain after Burns and Its Effect on the Cerebral Pain Network: A Prospective, Double-Blinded, Randomized Controlled Trial. J Clin Med. 2022 Jul 22;11(15):4255. doi: 10.3390/jcm11154255.
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart (Forventet)
1. juli 2019
Primær fullføring (Forventet)
31. august 2020
Studiet fullført (Forventet)
30. november 2020
Datoer for studieregistrering
Først innsendt
5. mars 2019
Først innsendt som oppfylte QC-kriteriene
5. mars 2019
Først lagt ut (Faktiske)
7. mars 2019
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
20. juni 2019
Siste oppdatering sendt inn som oppfylte QC-kriteriene
18. juni 2019
Sist bekreftet
1. juni 2019
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- HangangSHH-3
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Ubestemt
IPD-planbeskrivelse
after review
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Nei
Studerer et amerikansk FDA-regulert enhetsprodukt
Nei
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .